fig5

Figure 5. Pyramid showing the evolution profile of chemopreventive agents for neuroblastoma. While some retinoids and DFMO are used as part of maintenance therapy, some are still being characterized in clinical trials. A large group of lead candidates that show excellent chemopreventive properties are in the pipeline for clinical translation. In addition, a sizable group of potential candidates for neuroblastoma chemoprevention are currently being characterized.